%0 Journal Article
%A Auxiliadora Bajo, Maria
%A Rios Moreno, Francisco
%A Dolores Arenas, Maria
%A Deuesa Such, Ramon Jesus
%A Molina Higueras, Maria Jose
%A Delgado, Margarita
%A Molina, Pablo
%A Garcia Fernandez, Nuria
%A Martin Malo, Alejandro
%A Peiro-Jordan, Roser
%A Cannata-Andia, Jorge
%A Martin de Franciscorl, Angel Luis
%T Seguridad y efectividad del oxihidroxido sucroferrico en pacientesespañoles en diálisis: subanalisis del estudio VERIFIE
%D 2021
%@ 0211-6995
%U http://hdl.handle.net/10668/22412
%X Background and aims: In this study, we show the results of the subset of Spanish patients of the VERIFIE study, the first post-marketing study assessing the long-term safety and effectiveness of sucroferric oxyhydroxide (SFOH) in patients with hyperphosphatemia undergoing dialysis during clinical practice. Patients and methods: Patients undergoing hemodialysis and peritoneal dialysis with indication of SFOH treatment were included. Follow-up duration was 12–36 months after SFOH initiation. Primary safety variables were the incidence of adverse drug reactions (ADRs), medical events of special interest (MESIs), and variations in iron-related parameters. SFOH effectiveness was evaluated by the change in serum phosphorus levels.Results: A total of 286 patients were recruited and data from 282 were analyzed. Among those 282 patients, 161 (57.1%) withdrew the study prematurely and 52.5% received concomitant treatment with other phosphate binders. ADRs were observed in 35.1% of patients, the most common of which were gastrointestinal disorders (77.1%) and mild/moderate in severity (83.7%). MESIs were reported in 14.2% of patients, and 93.7% were mild/moderate. An increase in ferritin (386.66ng/mL vs 447.55ng/mL; p = 0.0013) and transferrin saturation (28.07% vs 30.34%; p = 0.043) was observed from baseline to the last visit (p = 0.0013). Serum phosphorus levels progressively decreased from 5.69mg/dL at baseline to 4.84mg/dL at the last visit (p < 0.0001), increasing by 32.2% the proportion of patients who achieved serum phosphorus levels ≤5.5mg/dL, with a mean daily SFOH dose of 1.98 pills/day. Conclusions: SFOH showed a favorable effectiveness profile, a similar safety profile to that observed in the international study with most adverse events of mild/moderate severity, and a low daily pill burden in Spanish patients in dialysis. 
%K Dialysis
%K Sucroferric oxyhydroxide
%K Phosphate binder
%K Safety
%K Clinical practice
%K Chronic kidney-disease
%K Phosphate binder pa21
%K Hemodialysis-patients
%K Hyperphosphatemia
%K Efficacy
%K Bone
%K Dialisis
%K Oxihidroxido sucroferrico
%K Captor de fosforo
%K Seguridad
%K Practica clinica
%~